Description
A STAT3 inhibitor; binds to the STAT3 SH2 domain (Ki = 136 nM) and inhibits G-CSF-induced activation of STAT3 in patient-derived AML cells (IC50s = 8-18 µM); induces apoptosis in patient-derived AML cells (EC50s = 6-50 µM); reduces viability of HepG2, Huh7, and PLC/PRF/5 hepatoma cells (IC50s = 10.19, 11.27, and 11.83 µM, respectively); reduces hepatic Pten deletion-induced hepatic macro- and microsteatosis which reduces the development of hepatocellular carcinomas in mice at 100 mg/kg; increases muscle fiber size in a murine Lewis lung carcinoma model of cancer cachexia at 12.5 mg/kg
Formal name: N-(1′,2-dihydroxy[1,2′-binaphthalen]-4′-yl)-4-methoxy-benzenesulfonamide
Synonyms:
Molecular weight: 471.5
CAS: 432001-19-9
Purity: ≥98%
Formulation: A crystalline solid
